Collaboration makes leukaemia treatment globally available

MyTomorrows and Spectrum Pharmaceuticals team up to provide access to liposome-encapsulated vincristine for the treatment of Philadelphia chromosome negative acute lymphoblastic leukaemia

In August 201, the US FDA approved liposome-encapsulated vincristine for treatment of this type of leukaemia.

Through myTomorrows’ internet-based platform, liposome-encapsulated vincristine is now also made available to patients and doctors in all other countries of the world, (except China and Taiwan) through an Early Access Program.

Dr. Ronald Brus, founder and CEO of myTomorrows, said: "We are pleased to make liposome-encapsulated vincristine available to leukaemia patients outside of the United States, in countries where the treatment has not yet receive market approval.”

Joseph Turgeon, president and COO of Spectrum Pharmaceuticals, said: "We look forward bringing this product to doctors and patients through myTomorrows’ global platform.

“It provides an additional option for acute lymphoblastic leukaemia patients whose disease is unresponsive to available therapies and underscores Spectrum’s efforts to combat this terrible disease.”